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Changing Therapy for Gastrinoma
ABSTRACT
Ellison, E. C., (1995) Forty-year appraisal of gastrinoma:
Back to the future. Annals of Surgery; 222, 511-524.
Objective: The author analyzed potential survival
determinants in gastrinoma to characterize a possi-
ble uniform staging system and to determine
whether complete surgical resection improves ex-
pected survival.
Summary and Background Data: Gastrinoma is an
indolent yet malignant neuroendocrine tumor.
The associated gastric acid hypersecretion can be
controlled medically. Staging of gastrinoma is
inconsistent and the role Of surgical resection
controversial.
Methods: Seventy-four patients with gastrinoma
with a minimum 5-year follow-up were assessed.
Cox’s proportional hazards regression model was
used to examine the association of risk factors with
survival.
Results: The following factors had no effect on
survival: age at diagnosis, sex, presence of lymph
node metastases, associated multiple endocrine
neoplasia, and method of ulcer treatment. The three
unique determinants of survival were primary
tumor size (relative risk 1.534; p=0.0005), liver
metastases (relative risk, 2.947; p=0.0209), and
complete surgical resection (relative risk 0.163;
p=0.0076). On the basis of these risk factors, a
uniform staging system is proposed and predictive
survival curves developed.
Conclusions: The primary determinants of survival
in gastrinoma are the size of the primary tumor and
liver metastases. Complete surgical resection re-
duces mortality, regardless of other factors.
Keywords: Gastrinoma
PAPER DISCUSSION
The study of risk factors and their implication on
survival in Zollinger-Ellison syndrome (ZES)
became possible with the introduction of potent
acid suppression medication with few patients
now dying from the consequences of high acid
secretion. Within a period of months two land-
mark articles have appeared on the natural
history and prognosis of the ZES by Ellison and
by Weber et al. [1]. The large numbers in both
series and the detailed analysis of their data have
for the first time allowed a more accurate
assessment of the factors determining the prog-
nosis. The analysis of the data in both series were
similar with the emphasis on various clinico-
pathological tumor characteristics such as gastri-
.noma size, location, metastases to liver or lymph
nodes and association to MEN-I.
In his study Ellison divided his patients into
two groups consisting of patients treatedbetween
1947-1979 (pre-H2 receptor antagonist era, 40
patients) and 1980 -1994 (H2 receptor antagonist
era, 34 patients). He categorized both groups with
regard to tumor characteristics, gastric opera-
tions, tumor resection and cause of death. The
analysis resulted in identifying three risk factors
which were associated with survival: liver me-
tastases, tumor size, and resection. On the basis of
these risk factors he proposed a staging system for
gastrinoma based on primary tumor size and
metastases. Tumor location, multicentricity and
lymph node metastases were not considered tobe
independent prognostic factors. He concluded
that regardless of the site of the primarytumor the
small tumor size and complete surgical resection
improved the survival.
Weber et al. based their findings on data
selected from 185 consecutive patients from the
National Institute of Health over a 15 year period.
Both series showed remarkable similar figures for
patients with MEN-I (Ellison 12% in the H2
receptor antagonist era, Weber 18%), histological
confirmation of ZES (82% vs. 89%), occurrence of
liver metastases (21% vs. 24%) and the location of
pancreatic (35% in the H2 era vs. 30%) and
duodenal primaries (26% in the H2 era vs. 30%).
However, Ellison reported on only 4% (3/74)
"lymph node primaries" while Weber found
gastrinoma tissue confined only to lymph nodes
in 24 (13%) of his 185 patients.412 HPB INTERNATIONAL
Unlike in the previous publication from the
same center Ellison did not analyse the prognostic
value of the MEN-I syndrome [2]. In this 1993
publication 20-year survival was appreciably
better in patients with the MEN-I syndrome
(58% vs. 31% without MEN-I syndrome), an
observation which is shared by Weber (93% vs.
68% 15-year survival, p=0.06). The most logical
explanation for this difference is the higher
incidence of associated liver metastases in the
sporadic group which suggests that the ZE
patients harbored more aggressive tumors.
Both authors used various statistical models to
determine the significance of tumor location and
size of tumor on prognosis. Their results indicate
that the anatomical site is not a determining
factor. Ellison suggests that tumor location is a
confounding co-variable of size and not an
independent factor for survival. But with pan-
creatic tumors being bigger in size when detected
and therefore more prone to metastasize to the
liver, location still may be an important factor
influencing survival.
The two studies agreed that there is a highly
significant correlation of primary tumor size, the
development of liver metastases and survival.
The ultimate prognosis is determined by the
presence of liver metastases; when liver meta-
stases were present the 10-year survival was
reduced from 90% to about 30%.
Our experience of 7 patients with liver meta-
stases (of a total of 34 patients with gastrinomas)
showed that survival can vary within a wide
range depending on the biological behaviour of
the tumor [3]. It is our impression that the
overall prognosis of metastatic gastrinoma to the
liver is good, even if multiple metastases are
present. Minimal extrahepatic disease seems to
be a favourable prognostic factor in these
patients [3].
Both authors finally concluded that with size
being one of the important factors for survival,
surgery has to focus on complete tumor
resection. In Ellison’s series as well as in others,
more than two thirds of all deaths in ZE
patients were caused by progression of the
disease with the development of metastases [4].
In another study Fraker also emphasizes the
importance of tumor resection on the basis of
his experience [5]. In his series medically
treated patients had a seven fold increased risk
of developing liver metastases when compared
to patients who had excision of the primary
tumor. These observations indicate routine
exploratory laparotomy in surgically fit patients
with excision of all macroscopic tumor and,
when feasible, of liver metastases.
While Ellison’s attempt at a new staging
system for gastrinomas is plausible, it is doubt-
ful whether the TNM classification is appro-
priate for endocrine tumors which have a
different biological behaviour, particularly with
regard to metastases [6]. Since survival is not
influenced by lymph node metastases the listed
lymph node status in the classification would
seem inappropriate. While tumor size is of
prognostic importance it is not clear how the
author derived the various sizes for primary
tumor staging (T1-4). Indeed 10-year survival
was similar in patients without liver metastases
regardless of tumor size when the primary
tumor was resected. Therefore, other than for
the presence of liver metastases, this classifica-
tion is of limited value for surgical decision
making or for predicting outcome. Neverthe-
less, it is to the author’s credit that he initiated
a new look at a staging system for gastrinoma
and other endocrine tumors. These data should
stimulate other centers to review their own
experience to refine an appropriate and prac-
tical classification.
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Small-Diameter PTFE Portosystemic Shunts"
Portocaval vs Mesocaval
ABSTRACT
Paquet, K.-J., Lazar, A., Koussouris, P., Hotzel, B., Gad,
H. A., Kuhn, R. and Kalk, J.-F. (1997) Mesocaval
interposition shunt with small-diameter polytetrafluoro-
ethylene grafts in sclerotherapy failure, British Journal of
Surgery; 82, 199-203.
Fifty-seven patients with failed sclerotherapy re-
ceived a mesocaval interposition shunt with an
externally supported, ringed polytetrafluoroethylene
prosthesis of either 10 or 12mm diameter. Thirty-one
patientshad Child-Pugh gradeA disease and 26 grade
B; all had a liver volume of 1000-2500 ml. Follow-up
ranged from 16 months to 6 years 3 months. Three
patients (5 per cent) died in the postoperative period.
There were two postoperative recurrences of variceal
haemorrhage and one recurrent bleed in the second
year after surgery. The cumulative shunt patency rate
was 95 per cent and the incidence of encephalopathy
9 per cent; the latter was successfully managed by
protein restriction and/or lactulose therapy. The
actuarial survival rate for the whole group at 6 years
was 78 per cent, for those with Child-Pugh gradeA 88
per cent and for grade B 67 per cent. Small-lumen
mesocaval interposition shunting achieves portal
decompression, preserves hepatopetal flow, has a
low incidence of shunt thrombosis, prevents recur-
rent variceal bleeding and is not associated with
significant postoperative encephalopathy.
Keywords: Portocaval shunt, mesocaval shunt, Sarfeh shunt,
narrow-diameter shunt
PAPER DISCUSSION
The place of surgical operations in the treatment
of portal hypertension has become much more
circumscribed. For the most part, initial treat-
ment, both emergency and elective, is non-
surgical and involves a direct attack on the
varices, either sclerotherapy or banding. Balloon
tamponade and vasoactive drugs represent ad-
juvant treatment only. Surgery is used when
sclerotherapy or banding fails. Because of the
post-operative incidence of hepatic failure and
encephalopathy, end-to-side portacaval shunt
was abandoned in favour of operations aimed
to maintain prograde portal flow and hepatic
perfusion, e.g. distal splenorenal shunt, small-
diameter side-to-side portacaval shunts, etc The
value of maintaining hepatic perfusion remains
largely theoretical. The operation of mesocaval
interposition shunt had the advantage of techni-
cal simplicity. However, although the initial
results seemed good, long-term outcome was
not so optimistic in terms of rebleeding and
encephalopathy. Graft thrombosis was common.